New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:13 EDTVRTXVertex announced data on on ALS-2200 are being presented at AASLD
Vertex Pharmaceuticals announced that data on ALS-2200, VX-135, an oral medicine Vertex is developing for the treatment of hepatitis C, are being presented for the first time at The Liver Meeting, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD. Data from viral kinetic study showed rapid reduction of HCV RNA with ALS-2200 (VX-135), Vertex’s oral nucleotide analogue in development for the treatment of hepatitis C.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
11:19 EDTVRTX Options with increasing implied volatility
Options with increasing implied volatility: HLF VRTX TRP CLX ETP VALE
07:55 EDTVRTXVertex should be bought into recent strength, says Wells Fargo
Subscribe for More Information
September 22, 2014
11:26 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: SHLD VRTX TRP AGNC
September 18, 2014
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
September 17, 2014
07:09 EDTVRTXVertex price target raised to $127 from $103 at Deutsche Bank
Subscribe for More Information
September 10, 2014
09:27 EDTVRTXVertex shares likely to advance further, says RBC Capital
Subscribe for More Information
September 9, 2014
11:47 EDTVRTXStocks with call strike movement; FSLR VRTX
First Solar (FSLR) March 80 call option implied volatility increased 2% to 42, Vertex (VRTX) January 105 call option implied volatility increased 6% to 41 according to IVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use